Many effective drugs that are already developed will not reach patients for years because the clinical trial system is the primary bottleneck. This delay is due to logistical and structural inefficiencies in testing, not a lack of scientific discovery.

Clinical trial protocols become overly complex because teams copy and paste from previous studies, accumulating unnecessary data points and criteria. Merck advocates for "protocol lean design," which starts from the core research question and rigorously challenges every data collection point to reduce site and patient burden.

The industry's standard practice of selecting sites based on pre-existing relationships and convenience—the "easy button"—is a primary driver of failure. This leads to 80% of activated sites missing enrollment targets and 30% enrolling zero patients, a massive, systemic inefficiency that data-driven approaches can solve.

The most valuable lessons in clinical trial design come from understanding what went wrong. By analyzing the protocols of failed studies, researchers can identify hidden biases, flawed methodologies, and uncontrolled variables, learning precisely what to avoid in their own work.

A common failure in biotech is viewing patients solely as data sources rather than as human partners in the development process. This perspective leads to unnecessarily complex protocols with high patient burden. The most successful firms build relationships with patient advocacy groups and design trials that respect the patient's experience.

Clinicians identify outdated control arms—like single-agent chemotherapy without newer targeted agents—as a major deterrent for patient trial participation. Patients are unwilling to be randomized to a therapy that doesn't reflect the current, more effective standard of care. This pressure is forcing sponsors and the FDA to design trials with more realistic comparator arms.

Instead of a total overhaul, we can accelerate trials with three changes: 1) A simple patient opt-in registry for trial participation. 2) Collaborative platform trials testing multiple drugs against one control group. 3) A shared database for all trial data, including failures.

Scientists often design trials to answer every possible academic question, which adds complexity and patient burden. Drug development trials should be ruthlessly focused on two things only: safety and efficacy. All other extraneous research can wait for post-approval studies.

Beyond medical side effects, clinical trials impose a significant 'procedural burden' on patients: frequent travel, extra blood draws, and endless questionnaires. This human cost must be minimized, as it can disrupt a patient's life and limit participation for those without strong support systems.